BioAge Labs Inc. (BIOA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 9 | 10 | 8 |
| Operating profit | $m | -93 | -106 | ||||||
| Net profit | $m | - | - | -40 | -64 | -71 | -81 | -94 | -86 |
| EPS reported | $ | -2.24 | -2.38 | ||||||
| Operating cashflow per share | $ | -2.27 | -1.95 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -2.29 | -1.96 | ||||||
| Free cash flow | $m | -82 | -88 | ||||||
| Net debt | $m | -276 | -319 | ||||||
| Book value equity | $m | 272 | 375 | ||||||
| Book value per share | $ | 7.57 | 8.36 | ||||||
| Number of shares | m | 35.93 | 44.84 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.75 | 1.27 | ||||||
| P/S LTM | x | 52.85 | 45.91 | ||||||
| P/FCF LTM | x | -5.77 | -5.40 | ||||||
| EV/EBITDA LTM | x | -3.66 | -3.11 | ||||||
| EV/Sales LTM | x | 32.47 | 28.00 | ||||||
| Earnings Yield LTM | % | -16.96% | -21.97% | ||||||
| FCF Yield | % | -17.32% | -18.53% | ||||||
| Quality | |||||||||
| ROE | % | -29.63% | -28.99% | ||||||
| ROIC | % | -33.38% | -28.08% | ||||||
| Operating margin | % | -10.31% | -10.26% | ||||||
| Gross margin | % | +100.00% | +99.39% | ||||||
| FCF/Sales | % | -915.46% | -850.69% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -14.81 | -31.07 | ||||||
| Net Debt/EBITDA | x | 2.30 | 0.76 | ||||||
| EBIT/Net interest | x | -133.11 | -378.19 | ||||||
| Net debt/market cap | % | +1.05% | 0.00% | ||||||
| Net debt/Equity | x | -1.01 | -0.85 | ||||||
| Gross debt/equity | x | 0.02 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free